Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $692.86M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.84M
Average 1.49M
Returns on capital
Sagimet Biosciences Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-45.8%
avg -7.7%
ROIC
-51.0%
avg -63.4%
ROA
-43.8%
avg -54.2%
Analysis
ROA is currently the strongest return metric at -43.8% versus its period average of -54.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
David A. Happel | Chief Executive Officer, President & Director | USD 943.88K | 64 | — | — |
Elizabeth Rozek | Chief Legal & Administrative Officer | USD 669.9K | 54 | 224.41K | 0.69% |
Andreas Grauer | Chief Medical Officer | USD 669.06K | 65 | 35.00K | 0.11% |
Thierry Chauche | Chief Financial Officer & Principal Accounting Officer | USD 598.05K | 50 | 50.00K | 0.15% |
Marie O'Farrell | Chief Scientific Officer | — | — | — | — |
Robert D'Urso | Senior Vice President of New Products | — | — | — | — |
Lucas Pelkmans | Co-Founder | — | — | — | — |
Urs Greber | Co-Founder | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 20, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$4.91M
Net Transaction Value
−$4.91M
Net selling
Most Active
Kemble George
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 14, 26Aug 14, 2026 | Kemble George Direct | Sell | $3.6M$3,591,579.77 |
| Aug 11, 26Aug 11, 2026 | Kemble George Direct | Sell | $201.1K$201,146.69 |
| Jul 20, 26Jul 20, 2026 | Happel David Direct | Sell | $497.1K$497,067.79 |
| Jul 20, 26Jul 20, 2026 | Rozek Elizabeth Direct | Sell | $81.8K$81,832.36 |
| Jul 20, 26Jul 20, 2026 | Kemble George Direct | Sell | $140.5K$140,529.13 |
| Feb 10, 26Feb 10, 2026 | Happel David Direct | Sell | $64.9K$64,864.99 |
| Feb 10, 26Feb 10, 2026 | Chauche Thierry Direct | Sell | $7K$7,032.71 |
| Feb 10, 26Feb 10, 2026 | Martins Eduardo Bruno Direct | Sell | $19.5K$19,511.13 |
| Feb 10, 26Feb 10, 2026 | Rozek Elizabeth Direct | Sell | $14.1K$14,054.44 |
| Nov 20, 25Nov 20, 2025 | Kemble George Direct | Sell | $290K$289,979.01 |
Summary
Insiders reported 0 buys worth $0.00 and 10 sells worth $4.91M over the last 12 months. That adds up to net selling of $4.91M. Kemble George was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Sagimet Biosciences Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about SGMT's management, answered from reported figures.
Who manages SGMT?
Sagimet Biosciences Inc. (SGMT) lists 8 active executives. The top listed executive is Andreas Grauer, Chief Medical Officer.
Are SGMT insiders buying or selling?
Recent insider activity shows net buying of $14.37M.
Continue the stock analysis
Jump to another research area for this company.